MedPath

Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Phase 3
Active, not recruiting
Conditions
Medulloblastoma
Anaplastic Medulloblastoma
Supratentorial Embryonal Tumor, Not Otherwise Specified
Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Drug: Leucovorin Calcium
Drug: Thiotepa
Drug: Methotrexate
Drug: Vincristine Sulfate
First Posted Date
2006-06-12
Last Posted Date
2024-09-30
Lead Sponsor
Children's Oncology Group
Target Recruit Count
91
Registration Number
NCT00336024
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Tulane University School of Medicine, New Orleans, Louisiana, United States

๐Ÿ‡บ๐Ÿ‡ธ

Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States

๐Ÿ‡บ๐Ÿ‡ธ

NYU Langone Hospital - Long Island, Mineola, New York, United States

and more 142 locations

Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Phase 2
Completed
Conditions
Clear Cell Renal Cell Carcinoma
Childhood Renal Cell Carcinoma
Clear Cell Sarcoma of the Kidney
Papillary Renal Cell Carcinoma
Stage I Renal Cell Cancer
Stage II Renal Cell Cancer
Rhabdoid Tumor of the Kidney
Stage I Renal Wilms Tumor
Stage IV Renal Wilms Tumor
Stage II Renal Wilms Tumor
Interventions
Drug: Doxorubicin Hydrochloride
Procedure: Conventional Surgery
Drug: Irinotecan Hydrochloride
Biological: Dactinomycin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Carboplatin
Drug: Vincristine Sulfate
Other: Laboratory Biomarker Analysis
Radiation: Radiation Therapy
First Posted Date
2006-06-12
Last Posted Date
2017-07-21
Lead Sponsor
Children's Oncology Group
Target Recruit Count
291
Registration Number
NCT00335556
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Eastern Maine Medical Center, Bangor, Maine, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Texas Southwestern Medical Center, Dallas, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Advocate Children's Hospital-Oak Lawn, Oak Lawn, Illinois, United States

and more 184 locations

Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis

Phase 3
Conditions
Nonneoplastic Condition
First Posted Date
2006-06-08
Last Posted Date
2013-09-17
Lead Sponsor
Children's Cancer and Leukaemia Group
Target Recruit Count
288
Registration Number
NCT00334672
Locations
๐Ÿ‡ฌ๐Ÿ‡ง

Birmingham Children's Hospital, Birmingham, England, United Kingdom

๐Ÿ‡ฌ๐Ÿ‡ง

Watford General Hospital, Herts, England, United Kingdom

๐Ÿ‡ฌ๐Ÿ‡ง

Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom

and more 9 locations

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

Phase 2
Conditions
Diffuse Large B Cell Lymphoma
Lymphoma, Non-Hodgkin
First Posted Date
2006-06-02
Last Posted Date
2006-09-26
Lead Sponsor
The Alvin and Lois Lapidus Cancer Institute
Target Recruit Count
27
Registration Number
NCT00333008
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Sinai Hospital of Baltimore, Baltimore, Maryland, United States

๐Ÿ‡บ๐Ÿ‡ธ

Northwest Hospital Center, Randallstown, Maryland, United States

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Phase 1
Completed
Conditions
Male Breast Cancer
HER2-positive Breast Cancer
Stage IV Breast Cancer
Recurrent Breast Cancer
Interventions
First Posted Date
2006-05-31
Last Posted Date
2017-07-26
Lead Sponsor
University of Washington
Target Recruit Count
30
Registration Number
NCT00331552
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment

Phase 3
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2006-05-29
Last Posted Date
2017-03-28
Lead Sponsor
National Cancer Institute, Naples
Target Recruit Count
300
Registration Number
NCT00331097
Locations
๐Ÿ‡ฎ๐Ÿ‡น

Azienda Ospedaliera G. Rummo, Benevento, BN, Italy

๐Ÿ‡ฎ๐Ÿ‡น

Policlinico Monteluce, Sant'Andrea delle Frate, PG, Italy

๐Ÿ‡ฎ๐Ÿ‡น

Universitร  Federico II, Cattedra di Oncologia Medica, Napoli, Italy

and more 5 locations

Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

Phase 2
Completed
Conditions
Metastatic Melanoma
Metastatic Kidney Cancer
Interventions
Drug: Natural Killer (NK) Lymphocytes
Biological: IL-2
Drug: Cyclophosphamide
Drug: Fludarabine
First Posted Date
2006-05-22
Last Posted Date
2012-11-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
8
Registration Number
NCT00328861
Locations
๐Ÿ‡บ๐Ÿ‡ธ

National Cancer Institute (NCI), Bethesda, Maryland, United States

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Phase 3
Suspended
Conditions
Lymphoma
First Posted Date
2006-05-11
Last Posted Date
2013-12-18
Lead Sponsor
Favrille
Target Recruit Count
480
Registration Number
NCT00324831
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Tower Cancer Research Foundation, Beverly Hills, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma

Phase 1
Completed
Conditions
Melanoma (Skin)
Interventions
Biological: Melan-A VLP vaccine, IMP321 adjuvant
Biological: adoptive immunotherapy
Biological: therapeutic autologous lymphocytes
Drug: cyclophosphamide
Drug: fludarabine phosphate
First Posted Date
2006-05-11
Last Posted Date
2012-11-20
Lead Sponsor
Prof. Serge Leyvraz
Target Recruit Count
8
Registration Number
NCT00324623
Locations
๐Ÿ‡จ๐Ÿ‡ญ

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

ยฉ Copyright 2025. All Rights Reserved by MedPath